×
About 873 results

ALLMedicine™ Adult T-cell Leukemia/lymphoma Center

Research & Reviews  327 results

Oral HDAC Inhibitor Tucidinostat (HBI-8000) in Patients with Relapsed or Refractory Adu...
https://doi.org/10.1111/cas.15431
Cancer Science; Utsunomiya A, Izutsu K et. al.

May 18th, 2022 - This multicenter, prospective Phase IIb trial evaluating the efficacy and safety of tucidinostat (HBI-8000) in patients with relapsed or refractory (R/R) adult T-cell leukemia/lymphoma (ATLL) was conducted in Japan. Eligible patients had R/R ATLL ...

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04639843

May 13th, 2022 - Background: T-cell lymphomas (TCLs) are a heterogeneous group of lymphoid malignancies defined by clonal proliferation of post-thymic T lymphocytes. Patients with newly diagnosed TCLs are most commonly treated with a CHOP (cyclophosphamide, doxoru...

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
https://clinicaltrials.gov/ct2/show/NCT04703192

May 10th, 2022 - This study was designed to evaluate the efficacy and safety of valemetostat tosylate monotherapy. The primary objective will evaluate objective response rate of valemetostat tosylate monotherapy as measured by blinded independent central review (B...

Spindle cell tumor with histiocytic and myogenic marker expression in the lymph node of...
https://doi.org/10.1016/j.prp.2022.153935
Pathology, Research and Practice; Kubo T, Hirayama Y et. al.

May 8th, 2022 - Carriers of oncogenic human T-cell leukemia virus type 1 (HTLV-1) can develop adult T-cell leukemia/lymphoma (ATLL). While an increasing number of animal models of HTLV-1 infection have revealed that malignant tumors with a histiocytic phenotype c...

Identification and characterization of a novel enhancer in the HTLV-1 proviral genome.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065021
Nature Communications; Matsuo M, Ueno T et. al.

May 4th, 2022 - Human T-cell leukemia virus type 1 (HTLV-1) is a retrovirus that causes adult T-cell leukemia/lymphoma (ATL), a cancer of infected CD4+ T-cells. There is both sense and antisense transcription from the integrated provirus. Sense transcription tend...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  10 results

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04639843

May 13th, 2022 - Background: T-cell lymphomas (TCLs) are a heterogeneous group of lymphoid malignancies defined by clonal proliferation of post-thymic T lymphocytes. Patients with newly diagnosed TCLs are most commonly treated with a CHOP (cyclophosphamide, doxoru...

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
https://clinicaltrials.gov/ct2/show/NCT04703192

May 10th, 2022 - This study was designed to evaluate the efficacy and safety of valemetostat tosylate monotherapy. The primary objective will evaluate objective response rate of valemetostat tosylate monotherapy as measured by blinded independent central review (B...

Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
https://clinicaltrials.gov/ct2/show/NCT00924170

Feb 8th, 2022 - BACKGROUND: Cluster of differentiation 25 (CD25) (p55, Tac or interleukin receptor 2 (IL2Ra) is strongly expressed in virtually 100 % of patients with adult T-cell leukemia/lymphoma (ATL), a highly aggressive human T-lymphotropic virus type 1 (HTL...

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT03905135

Feb 3rd, 2022 - Background: Mature T-cell cancers are a phenotypically heterogeneous group of malignancies which constitute 10-15% of all non-Hodgkin lymphomas (NHL). Patients with relapsed/refractory T cell lymphomas have limited therapeutic options, making new ...

Study of Lacutamab in Peripheral T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04984837

Dec 7th, 2021 - This is an open-label multicenter randomized non comparative phase II study to evaluate the safety and efficacy of the monoclonal anti-KIR3DL2 antibody Lacutamab in patients with Refractory/Relapsing (R/R) KIR3DL2 positive Peripheral T Cell Lympho...

see more →

News  11 results

An International Experience at Home
https://www.onclive.com/view/an-international-experience-at-home

Dec 5th, 2020 - Christopher Dittus, DO, MPH I often find myself in awe of physicians who travel around the world seeking out the 2 most desirable aspects of medicine—patients in desperate need of medical care and patients with genuinely novel pathology. The dow...

NCCN Guidelines Reflect Recent FDA Approvals for Hematologic Malignancies
https://www.onclive.com/view/nccn-guidelines-reflect-recent-fda-approvals-for-hematologic-malignancies

Dec 5th, 2020 - Meletios A. Dimopoulos, MD New options for patients with hematologic malignancies stemming from recent FDA approvals are making an impact on treatment strategies recommended in the National Comprehensive Cancer Network (NCCN) Clinical Practice Gu...

Targeted Agents Lead Treatment Advances in T-Cell Lymphoma
https://www.onclive.com/view/targeted-agents-lead-treatment-advances-in-t-cell-lymphoma

Dec 4th, 2020 - Jasmine M. Zain, MD Results from the phase III ECHELON-2 trial set a precedent for targeted therapy in T-cell lymphoma by showing the benefit of adding brentuximab vedotin (Adcetris) to standard chemotherapy in patients with advanced CD30-express...

Systemic Epstein-Barr Virus–Positive T-cell Lymphoma of Childhood
https://www.mdedge.com/dermatology/article/211566/pediatrics/systemic-epstein-barr-virus-positive-t-cell-lymphoma-childhood/page/0/2?channel=45

Nov 5th, 2019 - Comment Prevalence and Presentation Epstein-Barr virus is a ubiquitous γ-herpesvirus with tropism for B cells, affecting more than 90% of the adult population worldwide. In addition to infecting B cells, EBV is capable of infecting T and NK cells,.

Cobomarsen shows early promise for treating ATLL
https://www.mdedge.com/hematology-oncology/article/194089/lymphoma-plasma-cell-disorders/cobomarsen-shows-early-promise
Jennifer Smith

Feb 7th, 2019 - LA JOLLA, CALIF. – Phase 1 results suggest cobomarsen is well tolerated and can maintain or improve responses in patients with previously treated adult T-cell leukemia/lymphoma (ATLL).

see more →